65,437 trials
Pancreatic Ductal Adenocarcinoma
Primary: (Part A Experimental Dose Level 0 Only) Safety of the Combination of BMS-813160 Plus Nivolumab Plus Gemcitabine Plus Nab-paclitaxel as Measured by Frequency, Type, and…
Phrenic Nerve Paralysis
Primary: Diaphragm Excursion With Sigh — 4.2; 2.9 cm
Insulin Resistance · Endothelial Dysfunction
Primary: Change in Microvascular Blood Volume (MBV) During Insulin Infusion — 13.16; 11.3 ml/kg
Induction of Labor Affected Fetus / Newborn
Primary: Time From Foley Bulb Placement to Time of Delivery. — 24.2; 24.57 hr — p=0.8
Systolic Heart Failure
Primary: The Change in Platelet Aggregation Measured by the Accumetrics (VerifyNow P2Y12) Assay Between Baseline and Each Antiplatelet Medication — 66.4; 156.2 PRU (P2Y12…
Independent Living
Primary: Main Study: Effect of MiCAP With IF Alone Versus MiCAP With IF+EF on Site-level Outcomes of Adoption and Sustainability of CAPABLE — 72.22; 61.33 score on a scale — p=0.22
Respiratory Syncytial Virus
Primary: Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 7 Days After First Vaccination — 2; 6; 11; 17 Participants
Knee Osteoarthritis · Degenerative Joint Disease of Knee
Primary: Number of Participants Experiencing Treatment-related Adverse Events, as a Measure of Safety — 1; 7; 2 Participants
Hypertension in Pregnancy · Preeclampsia Severe · Gestational Hypertension
Primary: Prolonged Hospitalization — 13; 17 Participants
Severe Hypertriglyceridemia
Primary: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 — -56.00; -7.97 Percent of Change — p=<0.0001
Ureter Injury
Primary: Urine Jet Conspicuity Score — 4.1; 4.2; 2.5 score on a scale — p=<0.0001
Sleep Apnea, Obstructive · Sleep Apnea, Central
Primary: Breath Amplitude Correlation — .66 ICC the aggregated signal amplitudes
Sedentary Behavior · Aging · Activity, Motor
Primary: Change in Automaticity Score. — 17 Participants
Hemianopia, Homonymous · Hemianopsia, Homonymous
Primary: Humphrey Visual Field Perimetry — 108; 1272 visual angle degrees^2
Chronic Hepatitis D Infection
Primary: Improvement in Quantitative Serum HDV RNA Levels After 4-12 Weeks of Lonafarnib-based Therapy — 0.03; -1.78; -1.3; -1.85 log IU/mL